The biggest insurer in America is repairing itself, and the price already assumes it works

Overall Investment CaseiOur conclusion in one of three words. Qualifies means the business and the price both work. Watchlist means the business may work but the price or the evidence does not yet. Does Not Qualify means we would not buy it.

UnitedHealth Group is the largest health insurer in the United States, and we are watching it rather than buying it. The research timeframe is 5 years and beyond. The disposition is Watchlist. The business case is real. This company covers 48.5 million people through UnitedHealthcare and owns Optum, which delivers the care and fills the prescriptions that the insurance pays for. Nothing else in the industry is built that way at that size. Two things stop it qualifying, and they are separate things. The first is that the Department of Justice has an open criminal investigation and a separate open civil fraud investigation into how the company recorded patient diagnoses in Medicare Advantage, and the criminal inquiry has widened to take in Optum Rx and how the company pays the doctors it employs. No wrongdoing has been alleged and no charges have been brought. It is also not finished, and an unresolved investigation into the core of a business is not something a 5 year holding case can simply price in. The second is the price. At $370.95 the shares sit above our estimate of what the business is worth today.

Why It Could GrowiThe products, plans or market changes that could raise what this company earns over the next several years. Management saying so is not enough on its own.

Four things could lift earnings over the next 5 years and beyond. Medicare Advantage repricing. This is the part of the business that broke. Medicare Advantage is where the government pays a private insurer a fixed amount per person per year to cover an older patient. In 2025 the government cut what it paid, the Inflation Reduction Act changed the drug rules, and medical costs rose faster than the company had assumed. All three landed at once and adjusted earnings per share fell 40.9%, from $27.66 in 2024 to $16.35 in 2025. The company has since raised prices, left the counties where it could not make the numbers work, and the medical care ratio has come back from 89.1% for 2025 to 86.7% in the second quarter of 2026. That is the single biggest lever here, and it is already moving. Optum Health. This is the care delivery arm, with about 93 million consumers touched. Its model is value-based care, which means being paid a fixed sum to keep a patient healthy rather than a fee for each visit. Done well it earns more per patient than plain insurance does. Optum Rx. The pharmacy business took $154.7 billion of revenue in 2025 and $38.3 billion in the second quarter of 2026 alone. Scripts keep growing, and scale in buying drugs is hard for a smaller rival to copy. Claims automation and the cost programme. The operating cost ratio, which is what the company spends running itself as a share of revenue, was 12.7% in the second quarter of 2026 against 13.3% for 2025. Half a point of a $450 billion revenue base is real money. None of these four is a promise. Each needs the company to execute, and 2025 is the evidence that it can fail to.

What Makes It StrongiWhat stops a competitor taking the business, and whether that protection is getting stronger or weaker.

The member base. 48.5 million people at the end of June 2026 is the largest in the country, and scale is what sets what a hospital can charge you. Optum. Owning the clinics, the home health and the pharmacy benefit manager means a dollar of medical cost can be a dollar of someone else revenue inside the same company. No competitor of this size is integrated to the same degree. Pharmacy scale. Buying drugs for tens of millions of people wins prices a regional plan cannot get near. Data. Decades of claims and risk records across the whole country, which is what lets the company price a plan for a county it has operated in for twenty years. Two of those four, the Medicare risk coding and Optum Rx, are the subject of the open investigations. That is the uncomfortable part of this case and the reason the strength above does not settle it.

Financial HealthiWhether the company makes money, turns it into cash, and carries a sensible amount of debt. All three, because a company can pass one and fail another.

Profitability is average and recovering, not strong. Net margin was 4.9% in the second quarter of 2026, which is healthy for an insurer, and first-half earnings per share of $12.94 annualise to a return on equity above 20%. But adjusted earnings per share fell from $27.66 to $16.35 in a single year because of a funding change the company did not control, and a business that can lose two fifths of its earnings that fast is not a durable earner yet. Cash generation is strong. Operating cash flow was $19.7 billion for 2025 against reported earnings of about $12.1 billion, and $19.964 billion in the first half of 2026 alone. An insurer collects premiums before it pays claims, so cash arrives ahead of the cost. That is a genuine advantage and also the reason the next paragraph matters. Debt is medium. Total debt was $73.3 billion at the end of June 2026 against $31.5 billion of cash and short-term investments, so roughly $41.9 billion net. Debt to capital was 41.2%, down from 43.9% at the end of 2025 but still at the upper end of where this company has run. One figure to keep an eye on. Days claims payable, which is how many days of claims the reserves would cover, was 44.1 at the end of 2025 and 47.0 in the second quarter of 2026. Rising is good. Had it kept falling it would have raised the question of whether the reserves were being run thin to protect reported earnings.

Is Today's Price Attractive?iWhat we think the business is worth now against what the share costs today. A great company can still be a bad purchase at the wrong price.

No. On our estimate the shares look expensive. We value this on a multiple of normalised adjusted earnings rather than on a discounted cash flow. An insurer reported cash flow swings with claims reserves and with the float it holds, which makes a cash flow model unstable enough to produce almost any answer you want. Normalised adjusted earnings are taken at $23.00 a share. That sits between the $19.75 midpoint of this year guidance and the $27.66 the company earned in 2024, because the government funding cut is permanent and 2024 is not coming back as the normal. The multiple range is 13 to 15.5 times. The healthcare plans industry median is about 16.3 times forward earnings. Cigna trades near 9.3 times, CVS Health near 12.0 times and Elevance Health near 13.9 times. We use a discount to the median, not the premium this company used to command, because the two things that earned that premium are the two things under investigation. 13 times $23.00 is $299. 15.5 times $23.00 is $357. Rounded, our estimated fair value today is $300 to $360. The close on 8 October 2026 was $370.95. That is 3.0% above the top of the range. It is also 19.6% below the 52-week high of $461.62 set on 16 July 2026 and 44.9% above the 52-week low of $255.97 set on 27 March 2026. A share well below its high is not the same thing as a cheap share, and this is the case that difference was written for.

Potential OutcomesiThree estimates of where the share could be at the end of our timeframe. Bear is the bad case, Base is the likely one, Bull is the good one. They are estimates, not forecasts.

These are estimates, not forecasts, and every one of them starts from the same $370.95. The percentages are price change only. They do not include the dividend, which adds about 2.5% a year at today price. Bear case, $198 a share by 2031. That is 46.6% below today, or 11.8% a year. The investigations end in a large settlement and an agreement that puts a monitor over how the company codes diagnoses, Medicare Advantage margins stay compressed, adjusted earnings per share stalls near $18, and the market pays only 11 times for it. Base case, $390 a share by 2031. That is 5.1% above today, or 1.0% a year. Pricing and county exits do their work, adjusted earnings per share recovers to about $26, and the multiple settles at 15 times. Note what this says. Even if the recovery happens, today price gives you almost none of it, because today price already assumes it. Bull case, $540 a share by 2031. That is 45.6% above today, or 7.8% a year. The investigations close without charges, Medicare Advantage is repriced properly, Optum Health growth resumes, adjusted earnings per share reaches $30 and the multiple goes back to 18 times. We are not putting a probability on any of these. We do not have a method that would make one honest.

Main RisksiThe short version of the threats. The write-up explains each one.

The investigations. Open criminal and civil inquiries into Medicare diagnosis coding, now extending to Optum Rx and physician pay. A settlement would cost money. An agreement that changes how the company is allowed to record diagnoses would cost revenue every year after. Government rates. The government sets what Medicare Advantage pays. It cut that in 2025 and can cut it again, and roughly a third of this company earnings power sits on the other side of that decision. Medical cost trend. If people use more care than the premium assumed, the loss lands in the same year. There is no price rise available until the next annual cycle. Pharmacy benefit regulation. Optum Rx is large, profitable and politically exposed. Rules that force pharmacy benefit managers to pass rebates through would take real money out. Reserve adequacy. Claims are an estimate until they are paid. A reserve set too low flatters this year and is corrected in a later one.

What Would Change Our View?iThe specific developments that would make us reconsider. If none of them happens, nothing has changed.

Four specific things, and three of them would move us toward owning it. The Department of Justice closing both investigations with no charges and no agreement putting a monitor over diagnosis coding. This is the big one. It removes the reason this is a Watchlist rather than a judgement about price alone. The medical care ratio holding below 86% across a full year, not one quarter. That would show the repricing is structural rather than seasonal. Adjusted earnings per share back above $25 without one-off help. That is the test of whether the 2024 earnings power survived the funding cut. Days claims payable falling below 44 days for two quarters in a row. That one would move us the other way, because it would suggest the earnings recovery is being helped along by thinner reserves.

What We're Watching NextiThe results and milestones ahead that could strengthen or weaken the case.

Third quarter results on 13 October 2026, which is four days after this research was written. Analysts expect about $4.15 a share. The number that matters more is the medical care ratio, because that is what tells you whether 86.7% in the second quarter was the new level or a good quarter. After that, the government advance notice of Medicare Advantage rates for 2027, and the company own guidance for 2027. Neither has a date the company has published yet. Both would change the base case here more than a quarterly earnings figure would.

Year EstablishediThe year the company was founded. Not the year it listed its shares, which is usually later.

1977.

Company ProfileiWhat the company does, what it sells, and which countries it operates in.

UnitedHealth Group sells health insurance and delivers health care, in the United States. It runs in two halves. UnitedHealthcare is the insurer. It covered 48.5 million people at the end of June 2026 across employer plans, Medicare Advantage for older patients, and Medicaid for lower-income patients run under contract to individual states. Optum is everything else. Optum Health runs clinics, surgery centres and home health, and touched about 93 million consumers. Optum Insight sells data and technology to hospitals and other payers. Optum Rx is the pharmacy benefit manager, which negotiates drug prices and processes prescriptions. The business is overwhelmingly domestic. Revenue is in dollars and the main regulator is the United States government.

Business ModeliHow it makes money, where the sales come from, and how much it leans on any one customer or product.

Money comes in two ways. UnitedHealthcare collects a premium, monthly and in advance, and pays medical claims out of it. Optum charges fees for care delivered, for software, and for pharmacy services. On a consolidated basis, after stripping out the revenue Optum earns serving UnitedHealthcare internally, UnitedHealthcare is about 77% of the group and Optum about 23%. On a gross basis the segments look much bigger, because Optum Rx and Optum Health bill UnitedHealthcare for a great deal of work. In 2025 the four segments added to $621.0 billion of gross revenue against $447.6 billion consolidated. The $173.4 billion difference is the group selling to itself, and reading the segment figures without that in mind overstates Optum badly. There is no single customer worth worrying about. The concentration here is the government. Medicare and Medicaid pay a large share of UnitedHealthcare premiums, and the rates are set by the Centers for Medicare and Medicaid Services and by the states, not negotiated with a buyer. The company does not disclose a recurring revenue percentage, though premiums renew annually in practice.

Business StrengthiIts position against competitors, how loyal its customers are, and who it is actually up against.

This is the largest health insurer in the United States by both revenue and members. The competitive advantage is wide, and it rests on three things that are hard to assemble: the member base, the integration of insurance with owned care delivery, and the pharmacy scale. The main competitors are Elevance Health, The Cigna Group, CVS Health through Aetna, Humana in Medicare Advantage, and Centene in Medicaid. Humana is the closest comparison on Medicare Advantage specifically and has had the same funding problem. The company does not disclose a member retention figure.

Growth Track Record & PlansiHow fast it has grown in the past, what it plans next, and what evidence exists that the demand is there.

Revenue grew about 11.7% a year over the four years from $287.6 billion in 2021 to $447.6 billion in 2025. That part of the record is excellent. Earnings per share tells a different story, and this is the most important paragraph in this write-up. Adjusted earnings per share went $19.02, $22.19, $25.12, $27.66, and then $16.35. Four years of compounding at roughly 13% a year, then a 40.9% fall in one year. Measured end to end, adjusted earnings per share fell about 3.7% a year over those four years while revenue rose 11.7% a year. So growth here was real and then it was not. The company own long-stated target of 13% to 16% earnings per share growth has not been met, which is why we rate expansion progress as behind plan. The current plan is repair rather than expansion: reprice Medicare Advantage, exit the counties that cannot be made to work, take cost out of the operation, and keep growing Optum. Guidance issued in January for 2026 was revenue above $439.0 billion and adjusted earnings per share above $17.75. By the second quarter the company had raised the adjusted range to $19.50 to $20.00. Raising guidance is evidence the repair is working. It still leaves 2026 earnings 28% below 2024.

Financial PerformanceiSales, earnings, margins and cash flow, and which way each has been moving. Anything unusual or one-off is called out.

Revenue was $447.6 billion for 2025, with $223.8 billion in the first half of 2026. Earnings per share for 2025 were $13.23 reported and $16.35 adjusted. For the first half of 2026 they were $12.94 reported and $13.61 adjusted. The gap between reported and adjusted is mostly the amortisation of intangible assets from past acquisitions, which is a real cost of having bought things. Margins. The medical care ratio, which is the share of each premium dollar paid out in medical claims, was 89.1% for 2025 and 86.7% in the second quarter of 2026. Lower is better, and nearly two and a half points of improvement on this revenue base is the whole recovery story. Net margin was 4.9% in the second quarter of 2026. Cash flow. Operating cash flow was $19.7 billion for 2025 and $19.964 billion in the first half of 2026 alone, against reported earnings of about $12.1 billion for the whole of 2025. Cash conversion is well above 100% because premiums arrive before claims are paid. The quarterly release does not give a single free cash flow line, so the honest answer on free cash flow is that it is operating cash flow less capital spending and acquisitions, and the company reports those separately rather than netted. Explaining the unusual year. 2025 was not an operating failure in the ordinary sense. The company named three causes: the government cutting Medicare funding, the Inflation Reduction Act changing the drug benefit, and medical cost trends accelerating. Two of those three were done to it. That matters for how you read the recovery, and it matters more for how you read the risk, because the same three things can happen again.

Balance Sheet StrengthiCash, debt and what has to be repaid when. This is what decides whether a bad year is survivable.

Cash and short-term investments were $31.5 billion at the end of June 2026, up from $28.1 billion at the end of 2025. Total debt was $73.3 billion at the end of June 2026, down from $78.4 billion at the end of 2025. Net of cash that is roughly $41.9 billion. Debt to capital was 41.2%, improved from 43.9% six months earlier. Total equity was $100.1 billion at the end of 2025. The company does not publish a maturity schedule in its quarterly release, so the next refinancing dates are not stated here. On the evidence that is available the position is comfortable rather than tight: cash flow of nearly $20 billion in half a year against $73.3 billion of debt leaves plenty of room to service it. Could it withstand a difficult period? It just did one. 2025 was the difficult period, and the company came through it paying $7.9 billion of dividends and buying back $5.5 billion of stock. That is the useful answer to this question.

Management & GovernanceiWho runs the company, whether they deliver what they promise, how much they own, and any accounting or board concerns.

Stephen Hemsley has been chief executive since May 2025. He ran this company from 2006 to 2017 and joined it as chief operating officer in 1997, so he is not learning the business. He was brought back after the 2025 collapse, and the raised guidance since is the first evidence for him. Our assessment is average, and deliberately not strong. The crisis happened on a board he sat on. Judging him on the recovery he is six quarters into would be grading the exam he set. Governance concerns are serious, and this is the field that decides the disposition. There is an open Department of Justice criminal investigation and a separate open civil fraud investigation into how the company recorded patient diagnoses in Medicare Advantage. The criminal inquiry has widened to cover Optum Rx and how the company compensates the physicians it employs. The company says it has full confidence in its practices and is cooperating. The Department of Justice has not alleged misconduct and has not charged anyone. Being investigated is not being guilty, and we are not treating it as such. But the brief this research follows will not let an unresolved serious governance question sit inside a qualifying verdict, and that rule exists for exactly this situation. Insider ownership is about 0.7% of the shares, with the chief executive holding roughly 0.44%. Institutions hold about 89%. So management own money in the business is small in percentage terms, which is normal for a company of this size and still worth knowing.

Use of Company MoneyiWhere the profits go. Back into the business, into buying other companies, out as dividends, or into buying back its own shares.

Reinvestment goes mainly into Optum Health care delivery and into technology, alongside a steady flow of purchases of physician groups, clinics and home health businesses. The deals are frequent and individually small against a company of this size. Dividends. $7.9 billion paid in 2025 and $4.092 billion in the first half of 2026. The quarterly dividend was $2.21 a share paid in March 2026 and was raised to $2.32 paid in September 2026, which annualises to $9.28 and is a yield of 2.5% on the 8 October close. Buybacks. $5.5 billion in 2025 and $1.646 billion in the first half of 2026, with the company targeting at least $5.0 billion for the full year. The first-half pace is well below that target. Share dilution is not a problem here. The diluted share count went from 911 million for 2025 to 906 million in the second quarter of 2026. Buybacks are shrinking the count, slowly.

ValuationiThe ratios, the comparisons with similar companies and with its own history, and the working behind our estimate of what it is worth.

Market capitalisation is about $336.1 billion, which is 906 million diluted shares at the $370.95 close. On that close the shares trade at 18.8 times the $19.75 midpoint of this year adjusted earnings guidance, 22.7 times last year adjusted earnings of $16.35, and 28.0 times last year reported earnings of $13.23. Market capitalisation is 17.1 times 2025 operating cash flow of $19.7 billion. Against peers, 18.8 times forward earnings is a premium. Cigna is near 9.3 times, CVS Health near 12.0 times, Elevance Health near 13.9 times, and the healthcare plans industry median is about 16.3 times. Only Humana, at about 27.1 times, is more expensive, and Humana is more exposed to the same Medicare Advantage problem rather than less. Against its own history, the shares are 19.6% below the 52-week high of $461.62 and 44.9% above the 52-week low of $255.97. The 50-day average is $390.02 and the 200-day average is $357.25, so the price sits between the two. How we got to the range. Normalised adjusted earnings per share of $23.00, between this year $19.75 guidance midpoint and the $27.66 of 2024, because the funding cut is permanent and 2024 is not the normal to return to. A multiple of 13 to 15.5 times, which is a discount to the industry median rather than the premium this company used to earn, because the Medicare risk coding and Optum Rx that justified that premium are the subjects of the open investigations. 13 times $23.00 gives $299 and 15.5 times gives $357, rounded to an estimated fair value today of $300 to $360. The sector metrics that actually matter here are the medical care ratio, the operating cost ratio and days claims payable, and all three are given above with the periods they cover. A price to earnings ratio on an insurer tells you much less than the medical care ratio does, because the ratio is what decides whether the earnings exist at all.